Details for New Drug Application (NDA): 022341
✉ Email this page to a colleague
NDA 022341 describes VICTOZA, which is a drug marketed by Novo Nordisk Inc and is included in one NDA. It is available from three suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VICTOZA profile page.
The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.
The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.
Summary for 022341
| Tradename: | VICTOZA |
| Applicant: | Novo Nordisk Inc |
| Ingredient: | liraglutide |
| Patents: | 2 |
Pharmacology for NDA: 022341
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Suppliers and Packaging for NDA: 022341
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341 | NDA | Novo Nordisk | 0169-4060 | 0169-4060-12 | 2 SYRINGE, PLASTIC in 1 CARTON (0169-4060-12) / 3 mL in 1 SYRINGE, PLASTIC |
| VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341 | NDA | Novo Nordisk | 0169-4060 | 0169-4060-13 | 3 SYRINGE, PLASTIC in 1 CARTON (0169-4060-13) / 3 mL in 1 SYRINGE, PLASTIC |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | 18MG/3ML (6MG/ML) | ||||
| Approval Date: | Jan 25, 2010 | TE: | AP1 | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Feb 13, 2026 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Jul 9, 2037 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Expired US Patents for NDA 022341
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| Novo Nordisk Inc | VICTOZA | liraglutide | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Get Started Free | ⤷ Get Started Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
